User:19ag70/sandbox

Welcome to your sandbox!

Link to Project Resource Page

Practice Editing Here (Nov 15th in-class Wiki session work)

This is a place to practice clicking the "edit" button and practice adding references (via the citation button).

Task:

Find a peer-reviewed journal article on PubMed. Practice inserting your citation in the above space using the "cite" tool
Choose one "B-level" medical article on Wikipedia from the following list: https://wp1.openzim.org/#/project/Medicine/articles?quality=B-Class&importance=High-Class
Practice editing live on Wikipedia by finding a typo in the text or improving the clarity/readability of a sentence by adjusting a few words in a sentence.

Assignment # 3- please post an anonymous copy here!

Proposed sentence to change	Proposed change	Rationale	Controversy/more rationale	Critique of source
"However, newer therapies including diflunisal, an anti-inflammatory drug, and inotersen and patisiran, drugs which prevent misfolded protein formation, have shown early promises in slowing disease progression. The latter two drugs have shown their benefit in neurological impairment scores and quality of life measures."	New drug therapies include diflunisal, inotersen, and patisiran. Diflunisal binds to misfolded mutant TTR protein to prevent its buildup, similar to how tafamidis works. Low-certainty evidence indicates that it reduces worsening of peripheral neuropathy and disability from disease progression. Inotersen blocks gene expression of both wild-type and mutant TTR, reducing amyloid precursor. Moderate-certainty evidence suggests that it reduces worsening of peripheral neuropathy. Long-term efficacy and safety of intersen use in people with mutant TTR-related amyloidosis is still being evaluated in a phase-3 clinical trial as of 2021. Both diflunisal and inotersen may also reduce decreases in quality-of-life, though the evidence for this effect is yet unclear. Patisiran functions similarly to inotersen. Moderate-certainty evidence suggests that patisiran reduces worsening of peripheral neuropathy and disability from disease progression. Additionally, low-certainty evidence suggests that patisiran reduces decreases in quality-of-life and slightly reduces the rate of adverse events versus placebo. There is no evidence of an effect on mortality rate. (Magrinelli)	We expanded on the different types of therapies available with a brief description of their mechanism. We ensured to maintain the hyperlinks to their Wikipedia pages in case readers want to read more about each drug. These will be combined with our colleague’s updates of the international approvals and guideline suggestions. We chose to include more updated information about clinically relevant patient outcomes, along with an indication of the strength/certainty of the evidence (‘low,’ ‘moderate’). We added a time reference for comments regarding ongoing study so readers are aware of when this info may become outdated. We also changed sentences to use people-centred language. Sources being added: https://en.wikipedia.org/wiki/Inotersen https://en.wikipedia.org/wiki/Diflunisal en.wikipedia.org/wiki/Peripheral_neuropathy Magrinelli F, Fabrizi GM, Santoro L, et al. Pharmacological treatment for familial amyloid polyneuropathy. Cochrane Database Syst Rev. 2020;4(4):CD012395. Published 2020 Apr 20. doi:10.1002/14651858.CD012395.pub2	Citation #29 (Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324(1):79-89. doi:10.1001/jama.2020.5493) currently on the wiki page is an article that in turn cites Berk, Benson and Adams for info on diflunisal, inotersen and patisiran respectively. Magrinelli directly reviews these articles and the inferences made by Gertz and Dispenzieri are actually somewhat unsupported. For example, the article states that inotersen “demonstrated a significant slowing of the progression of the disease, measured by the neurologic impairment score and improved quality of life,” citing Benson for this assertion. However, Benson did not report disability due to FAP progression and the effect of inotersen (and diflunisal) on quality of life measures are not quite as significant or certain as the author suggests. What we have written here is directly from Magrinelli’s review (and therefore Berk, Benson and Adams), and does not overstate the certainty or significance of the finding associated with these three drugs.	Magrinelli F, Fabrizi GM, Santoro L, et al. Pharmacological treatment for familial amyloid polyneuropathy. Cochrane Database Syst Rev. 2020;4(4):CD012395. Published 2020 Apr 20. doi:10.1002/14651858.CD012395.pub2 This resource provides the most comprehensive and generalizable overview of the nonsurgical treatment options for familial amyloid polyneuropathy (a.k.a. transthyretin-related hereditary amyloidosis). It is a recent article published in the Cochrane Database of Systematic Reviews. There are no significant areas of concern with respect to bias or validity for the purposes of our use of this article.

What to post on the Wikipedia article talk page (part of assignment 3)

This will also be covered on Nov 15th in class. Your group should use the below template to share an outline of your proposed improvements (including your new wording and citations). Article talk pages are not places to share your assignment answers. The Wikipedia community will be more interested in viewing your exact article improvement suggestions including where you plan to improve the article (which section), what wording you suggest, and the exact citation (Note: all citations must meet WP:MEDRS)
You will not be able to paste citations directly from your sandbox to talk pages (unless you are interested in editing/learning Wiki-code in the "source editing" mode). We suggest re-adding your citations on the talk page manually (using the cite button and populating the citation by pasting in the DOI, website, or PMID). You will have to repeat this process yet again when you edit the actual article live.
Talk Page Template: Wikipedia:CARL Medical Editing Initiative/Fall 2021/Talk Page Template